Sanofi-Aventis’ novel, once-daily diabetes treatment lixisenatide has successfully met its phase III glucose blood level and glycaemic control endpoints.
http://www.inpharm.com/news/lixisenatide-scores-phase-iii-trial
http://www.inpharm.com/news/lixisenatide-scores-phase-iii-trial